First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial - PubMed
3 hours ago
- #immunotherapy
- #CLDN18.2
- #gastric cancer
- First-line zolbetuximab combined with mFOLFOX6 and nivolumab shows promise in treating unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.
- The phase 2 ILUSTRO trial demonstrated a median progression-free survival (PFS) of 14.8 months overall and 18.0 months in patients with CLDN18.2-high tumors.
- Objective response rates were 62.1% overall and 68.1% in CLDN18.2-high patients, indicating significant efficacy.
- Common treatment-emergent adverse events included nausea (80.5%) and decreased appetite (72.7%).
- The results support further randomized evaluation in the ongoing phase 3 LUCERNA study for CLDN18.2-positive and PD-L1-positive mG/GEJ adenocarcinoma patients.